Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : NTB003
Therapeutic Area : Immunology
Study Phase : IND Enabling
Recipient : Biocytogen
Deal Size : Inapplicable
Deal Type : Inapplicable
Biocytogen and Nanjing Chia Tai Tianqing Announce IND Approval in China for NTB003
Details : NTB003 is a second-generation fully human anti-IGF-1R monoclonal antibody, being investigated for thyroid eye disease.
Product Name : BCG009
Product Type : Antibody
Upfront Cash : Inapplicable
June 04, 2025
Lead Product(s) : NTB003
Therapeutic Area : Immunology
Highest Development Status : IND Enabling
Recipient : Biocytogen
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Fosaprepitant
Therapeutic Area : Gastroenterology
Study Phase : Approved FDF
Sponsor : Techdow USA
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Under the agreement, CTTQ will manufacture Fosaprepitant, a substance P/neurokinin-1 (NK1) receptor antagonist, for Injection, the therapeutic generic equivalent of Emend, and will be sold under the Techdow USA Label.
Product Name : Emend-Generic
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
August 22, 2023
Lead Product(s) : Fosaprepitant
Therapeutic Area : Gastroenterology
Highest Development Status : Approved FDF
Sponsor : Techdow USA
Deal Size : Undisclosed
Deal Type : Collaboration